Latest Insider Transactions at Edwards Lifesciences Corp (EW)
This section provides a real-time view of insider transactions for Edwards Lifesciences Corp (EW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edwards Lifesciences Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edwards Lifesciences Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-7.85%
|
$489,375
$87.79 P/Share
|
|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
535
-2.22%
|
$48,150
$90.0 P/Share
|
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
535
+2.18%
|
$24,075
$45.28 P/Share
|
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$435,000
$87.54 P/Share
|
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
|
May 30
2024
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Direct |
8,617
-11.22%
|
$749,679
$87.68 P/Share
|
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-15.54%
|
$506,250
$90.45 P/Share
|
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
|
May 11
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,198
-3.77%
|
$103,028
$86.72 P/Share
|
|
May 11
2024
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,854
-3.58%
|
$245,444
$86.72 P/Share
|
|
May 11
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
814
-1.7%
|
$70,004
$86.72 P/Share
|
|
May 11
2024
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
821
-2.61%
|
$70,606
$86.72 P/Share
|
|
May 11
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
21
-0.01%
|
$1,806
$86.72 P/Share
|
|
May 11
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
377
-1.58%
|
$32,422
$86.72 P/Share
|
|
May 11
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.44%
|
$84,710
$86.72 P/Share
|
|
May 11
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
827
-1.07%
|
$71,122
$86.72 P/Share
|
|
May 11
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.32%
|
$19,694
$86.72 P/Share
|
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.48%
|
$435,000
$87.81 P/Share
|
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.66%
|
$225,000
$45.28 P/Share
|
|
May 08
2024
|
Leslie C. Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+50.0%
|
-
|
|
May 08
2024
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,054
+34.89%
|
-
|
|
May 08
2024
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+9.23%
|
-
|
|
May 08
2024
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+22.09%
|
-
|
|
May 08
2024
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+27.25%
|
-
|
|
May 08
2024
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+6.13%
|
-
|
|
May 08
2024
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,054
+3.26%
|
-
|
|
May 07
2024
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
447
-1.4%
|
$37,995
$85.09 P/Share
|
|
May 07
2024
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+18.02%
|
-
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
857
-3.46%
|
$72,845
$85.6 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-2.31%
|
$49,810
$85.09 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
857
+3.27%
|
$30,852
$36.75 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
7,560
+14.18%
|
-
|
|
May 07
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-1.28%
|
$52,615
$85.09 P/Share
|
|
May 07
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,700
+12.17%
|
-
|
|
May 07
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
609
-0.78%
|
$51,765
$85.09 P/Share
|
|
May 07
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
32,025
+29.21%
|
-
|
|
May 07
2024
|
Wayne Markowitz GM & SVP, Surgical |
BUY
Grant, award, or other acquisition
|
Direct |
3,350
+23.93%
|
-
|
|
May 07
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-1.02%
|
$15,130
$85.09 P/Share
|
|
May 07
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,445
+12.27%
|
-
|
|
May 07
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-2.43%
|
$67,150
$85.09 P/Share
|
|
May 07
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,075
+25.39%
|
-
|
|
May 07
2024
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
647
-0.81%
|
$54,995
$85.09 P/Share
|
|
May 07
2024
|
Bernard J Zovighian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,500
+29.43%
|
-
|
|
May 07
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
695
-0.31%
|
$59,075
$85.09 P/Share
|
|
May 07
2024
|
Larry L Wood Global President TAVR & Surg |
BUY
Grant, award, or other acquisition
|
Direct |
8,725
+3.73%
|
-
|
|
May 07
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.02%
|
$3,910
$85.09 P/Share
|
|
May 07
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
7,125
+3.71%
|
-
|
|
May 06
2024
|
Bernard J Zovighian CEO |
BUY
Open market or private purchase
|
Indirect |
580
+15.08%
|
$49,300
$85.74 P/Share
|
|
May 06
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
259
-0.15%
|
$22,015
$85.25 P/Share
|